UBS Global Biopharma Conference 2026
Logotype for Exelixis Inc

Exelixis (EXEL) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Exelixis Inc

UBS Global Biopharma Conference 2026 summary

17 Nov, 2026

Strategic transition and priorities

  • Transitioning from a CABOMETYX-centered business to a multi-franchise model, with potential zanzalintinib approval and a PDUFA date expected early next year.

  • Near-term priorities include sustaining CABOMETYX performance, advancing zanzalintinib development and pre-commercial work, and maintaining early-pipeline investment and expense discipline.

  • Seven pivotal zanzalintinib studies make up wave one; a second wave could offer larger opportunities, with a frontline RCC study expected to anchor it.

CABOMETYX and RCC market dynamics

  • LITESPARK-011 showed a PFS benefit but no statistically significant OS advantage; sequencing versus combination, tolerability and treatment duration remain considerations for patients and physicians.

  • Increased use of lenvatinib/belzutifan in second line could shift some lenvatinib use away from first line; first-line share gains may partly offset second-line share pressure.

  • LITESPARK-012's failure creates an opportunity to invest in frontline RCC; the frontline study is among the key wave-two zanzalintinib opportunities.

  • Development is aimed at future RCC treatment pathways, including more patients receiving adjuvant pembrolizumab; LITESPARK-033 targets the post-adjuvant frontline setting and LITESPARK-034 a later-line setting.

  • Management views CABOMETYX as the TKI of choice for the 2020s and zanzalintinib as the potential TKI of choice for the 2030s.

NET opportunity and CABOMETYX commercial factors

  • The second-line-or-later oral NET market is estimated at $1B; management said the aspirational peak-sales goal remains unchanged, while the indolent disease can delay treatment starts and shift the launch curve.

  • NET market-share and patient-share data indicate uptake; management aims to capture share across the market, supported by CABINET data and high share of voice in a largely generic market.

  • 340B-related sales variability reflects industry and seasonal dynamics; annual, rather than quarterly, guidance is intended to reflect results over the full year.

  • Business planning uses January 1, 2031 as the best estimate for generic CABOMETYX availability; legal challenges are being managed as they arise.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Exelixis